Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis
- PMID: 2307402
- DOI: 10.1002/hep.1840110213
Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis
Abstract
Organic nitrates were reported to reduce portohepatic venous pressure gradient in patients with cirrhosis. However, these drugs lower arterial pressure and are well known to induce tolerance. The aim of the present study was to assess the hemodynamic effects of molsidomine, an antianginal agent, which does not induce tolerance and has little effect on arterial pressure in patients with normal liver, in 13 patients with alcoholic cirrhosis. Wedged hepatic vein pressure (-11%, p less than 0.01), portohepatic venous pressure gradient (-15%, p less than 0.005), hepatic blood flow (-17.4%, p less than 0.005), mean arterial pressure (-13.5%, p less than 0.01) and cardiac output (-17%, p less than 0.001) were significantly reduced by molsidomine. Free hepatic vein pressure, intrinsic hepatic clearance indocyanine green, heart rate and systemic vascular resistances were not significantly modified. There was no correlation between the decrease in portohepatic venous pressure gradient and the reduction in mean arterial pressure on one hand and the decrease in cardiac output on the other hand. We therefore conclude that in patients with cirrhosis, molsidomine has effects similar to nitrates on systemic and splanchnic hemodynamics.
Similar articles
-
Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis.Hepatology. 1991 Jun;13(6):1181-4. Hepatology. 1991. PMID: 2050332
-
Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis.J Hepatol. 1991 Sep;13(2):179-86. doi: 10.1016/0168-8278(91)90812-p. J Hepatol. 1991. PMID: 1744422 Clinical Trial.
-
Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.J Hepatol. 1996 Apr;24(4):430-5. doi: 10.1016/s0168-8278(96)80163-2. J Hepatol. 1996. PMID: 8738729 Clinical Trial.
-
Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis.Br J Clin Pharmacol. 1996 May;41(5):409-13. doi: 10.1046/j.1365-2125.1996.03279.x. Br J Clin Pharmacol. 1996. PMID: 8735682 Free PMC article.
-
Peculiar characteristics of portal-hepatic hemodynamics of alcoholic cirrhosis.World J Gastroenterol. 2014 Jul 7;20(25):8005-10. doi: 10.3748/wjg.v20.i25.8005. World J Gastroenterol. 2014. PMID: 25009370 Free PMC article. Review.
Cited by
-
Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.Br J Clin Pharmacol. 1991 Sep;32(3):399-401. doi: 10.1111/j.1365-2125.1991.tb03919.x. Br J Clin Pharmacol. 1991. PMID: 1777378 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources